Concepedia

Author

Eduardo Mysler

AbbVie (United States)ORCID

Also Known As

E Mysler, E. Mysler, E.F. Mysler, Eduardo F Mysler, Eduardo F. Mysler, Eduardo Mysler, G. Leon, Mc Basta, Mysler, Eduardo F.

162

Publications

18.9K

Citations

40

H-Index

49

Concepts

All Affiliations

AbbVie (United States)Cliniques Universitaires Saint-LucCharité - Universitätsmedizin BerlinMetroplex Clinical Research CenterThe University of Texas Southwestern Medical Center
EM

About

Eduardo Mysler is an author at AbbVie (United States) specializing in medicine, autoimmune disease, and rheumatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

10

3.5K

2

Education

1

1

35

3

Cell Biology

1

1

200

4

Epidemiology

1

1

18

5

Gastroenterology

1

1

700

Eduardo Mysler

×

48

Publications

11.5K

Citations

33

H-Index

YearCitations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma,

Annals of the Rheumatic Diseases

2020

2.6K

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra,

Annals of the Rheumatic Diseases

2022

1.6K

Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

Gerald B. Appel, Gabriel Contreras, Mary Anne Dooley,

Journal of the American Society of Nephrology

2009

1.1K

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

Mark C. Genovese, James D. McKay, Eduardo Mysler,

Arthritis & Rheumatism

2008

853

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Thomas J. Schnitzer, Gerd R Burmester, Eduardo Mysler,

The Lancet

2004

700

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

Michael E. Farkouh, Howard S. Kirshner, Robert A. Harrington,

The Lancet

2004

490

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall,

The Lancet

2017

479

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Roy Fleischmann, Aileen L. Pangan, In‐Ho Song,

Arthritis & Rheumatology

2019

410

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study

Eduardo Mysler, Alberto Spindler, Renato Guzmán,

Arthritis & Rheumatism

2013

345

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Michelle Petri, Daniel J. Wallace, Alberto Spindler,

Arthritis & Rheumatism

2013

238

Page 1